{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T23:21:27Z","timestamp":1762298487207},"reference-count":53,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2016,10,20]],"date-time":"2016-10-20T00:00:00Z","timestamp":1476921600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0164762","type":"journal-article","created":{"date-parts":[[2016,10,20]],"date-time":"2016-10-20T17:51:09Z","timestamp":1476985869000},"page":"e0164762","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":13,"title":["CSF Biomarkers and Its Associations with 18F-AV133 Cerebral VMAT2 Binding in Parkinson\u2019s Disease\u2014A Preliminary Report"],"prefix":"10.1371","volume":"11","author":[{"given":"Rui","family":"Gao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangjian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueqi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aimin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gwenn","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dean F.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2016,10,20]]},"reference":[{"issue":"3","key":"ref1","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1002\/ana.22311","article-title":"Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression","volume":"69","author":"M Shi","year":"2011","journal-title":"Ann Neurol"},{"issue":"4","key":"ref2","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s00702-011-0736-0","article-title":"CSF biomarkers in different phenotypes of Parkinson disease","volume":"119","author":"KA Jellinger","year":"2012","journal-title":"J Neural Transm"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3389\/fneur.2012.00187","article-title":"Cerebrospinal fluid biomarker candidates for parkinsonian disorders","volume":"3","author":"R Constantinescu","year":"2013","journal-title":"Front Neurol"},{"issue":"Pt 3","key":"ref4","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1093\/brain\/awq008","article-title":"DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson\u2019s disease","volume":"133","author":"Z Hong","year":"2010","journal-title":"Brain"},{"issue":"10","key":"ref5","first-page":"1277","article-title":"Association of cerebrospinal fluid \u03b2-amyloid 1\u201342, T-tau, Ptau181, and \u03b1-synuclein levels with clinical features of drug-na\u00efve patients with early Parkinson disease","volume":"70","author":"JH Kang","year":"2013","journal-title":"JAMA Neurol"},{"issue":"3","key":"ref6","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S1474-4422(11)70014-X","article-title":"\u03b1-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study","volume":"10","author":"B Mollenhauer","year":"2011","journal-title":"Lancet Neurol"},{"issue":"15","key":"ref7","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1002\/mds.22594","article-title":"Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson\u2019s disease","volume":"24","author":"Y Compta","year":"2009","journal-title":"Mov Disord"},{"issue":"1","key":"ref8","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1212\/WNL.0000000000001098","article-title":"CSF biomarkers and clinical progression of Parkinson disease","volume":"84","author":"S Hall","year":"2015","journal-title":"Neurology"},{"issue":"5","key":"ref9","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1136\/jnnp-2012-303808","article-title":"Cerebrospinal fluid amyloid-\u03b2 and phenotypic heterogeneity in de novo Parkinson&apos;s disease","volume":"84","author":"G Alves","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"ref10","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s00401-013-1121-x","article-title":"Longitudinal assessment of tau and amyloid beta in cerebrospinal fluid of Parkinson disease","volume":"126","author":"J Zhang","year":"2013","journal-title":"Acta Neuropathol"},{"issue":"3","key":"ref11","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/ene.12176","article-title":"Reduced \u03b1-synuclein levels in cerebrospinal fluid in Parkinson&apos;s disease are unrelated to clinical and imaging measures of disease severity","volume":"21","author":"KD van Dijk","year":"2014","journal-title":"Eur J Neurol"},{"issue":"2","key":"ref12","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s12035-009-8059-y","article-title":"Protective actions of the vesicular monoamine transporter 2 (VMAT2) in monoaminergic neurons","volume":"39","author":"TS Guillot","year":"2009","journal-title":"Mol Neurobiol"},{"issue":"4","key":"ref13","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.nucmedbio.2013.12.017","article-title":"Comparison of <sup>99m<\/sup>Tc-TRODAT-1 SPECT and <sup>18<\/sup>F-AV-133 PET imaging in healthy controls and Parkinson&apos;s disease patients","volume":"41","author":"IT Hsiao","year":"2014","journal-title":"Nucl Med Biol"},{"issue":"9","key":"ref14","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1002\/syn.21572","article-title":"Quantitative analysis of binding sites for 9-fluoropropyl-(+)-dihydrotetrabenazine ([\u00b9\u2078F] AV-133) in a MPTP-lesioned PD mouse model","volume":"66","author":"KT Chao","year":"2012","journal-title":"Synapse"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1471-2377-14-79","article-title":"PET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with <sup>18<\/sup>F-AV-133 (florbenazine) in patients with Alzheimer&apos;s disease and Lewy body disorders","volume":"14","author":"A Siderowf","year":"2014","journal-title":"BMC Neurol"},{"issue":"2","key":"ref16","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.pscychresns.2006.12.002","article-title":"FDG-PET and CSF phospho-tau for prediction of cognitive decline in mild cognitive impairment","volume":"155","author":"A Fellgiebel","year":"2007","journal-title":"Psychiatry Res"},{"issue":"5","key":"ref17","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1001\/jamaneurol.2014.4829","article-title":"Nonlinear Association between Cerebrospinal Fluid and Florbetapir F-18 \u03b2-Amyloid Measures across the Spectrum of Alzheimer Disease","volume":"72","author":"JB Toledo","year":"2014","journal-title":"JAMA Neurol"},{"issue":"4","key":"ref18","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.biopsych.2004.05.014","article-title":"Association of elevated phospho-tau levels with Alzheimer-typical 18F-fluoro-2-deoxy-D-glucose positron emission tomography findings in patients with mild cognitive impairment","volume":"56","author":"A Fellgiebel","year":"2004","journal-title":"Biol Psychiatry"},{"issue":"Pt 3","key":"ref19","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1093\/brain\/awu367","article-title":"Independent information from cerebrospinal fluid amyloid-\u03b2 and florbetapir imaging in Alzheimer&apos;s disease","volume":"138","author":"N Mattsson","year":"2015","journal-title":"Brain"},{"issue":"4","key":"ref20","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.pneurobio.2011.09.005","article-title":"The Parkinson Progression Marker Initiative (PPMI)","volume":"95","author":"K Marek","year":"2011","journal-title":"Prog Neurobiol"},{"issue":"4","key":"ref21","doi-asserted-by":"crossref","first-page":"783","DOI":"10.3233\/JPD-150682","article-title":"Associations between Cerebrospinal Fluid Biomarkers and Cognition in Early Untreated Parkinson&apos;s Disease","volume":"5","author":"RE Skogseth","year":"2015","journal-title":"J Parkinsons Dis"},{"issue":"5","key":"ref22","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s00401-013-1148-z","article-title":"CSF \u03b1-synuclein improves diagnostic and prognostic performance of CSF tau and A\u03b2 in Alzheimer&apos;s disease","volume":"126","author":"JB Toledo","year":"2013","journal-title":"Acta Neuropathol"},{"key":"ref23","unstructured":"Gaser C. Voxel-based morphometry extension to SPM8. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/dbm.neuro.unijena.de\/vbm\/\" xlink:type=\"simple\">http:\/\/dbm.neuro.unijena.de\/vbm\/<\/ext-link> 2014."},{"issue":"2","key":"ref24","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00415-006-0322-9","article-title":"18F-FP-CIT PET imaging and SPM analysis of dopamine transporters in Parkinson&apos;s disease in various Hoehn &amp; Yahr stages","volume":"254","author":"J Wang","year":"2007","journal-title":"J Neurol"},{"issue":"1","key":"ref25","first-page":"20","article-title":"Associations between <sup>18<\/sup>F-AV133 Cerebral VMAT2 Binding and Plasma LDL and HDL Levels in Parkinson\u2019s Disease","volume":"1","author":"R Gao","year":"2016","journal-title":"J Neuroimaging Psychiatry Neurol"},{"issue":"3","key":"ref26","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1212\/01.WNL.0000076181.39162.FC","article-title":"Increased ventral striatal monoaminergic innervation in Tourette syndrome","volume":"61","author":"RL Albin","year":"2003","journal-title":"Neurology"},{"issue":"9","key":"ref27","doi-asserted-by":"crossref","first-page":"e75952","DOI":"10.1371\/journal.pone.0075952","article-title":"Brain imaging of vesicular monoamine transporter type 2 in healthy aging subjects by <sup>18<\/sup>F-FP-(+)-DTBZ PET","volume":"8","author":"KJ Lin","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"ref28","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.parkreldis.2014.10.026","article-title":"Parkinson&apos;s disease severity levels and MDS-Unified Parkinson&apos;s Disease Rating Scale","volume":"21","author":"P Mart\u00ednez-Mart\u00edn","year":"2015","journal-title":"Parkinsonism Relat Disord"},{"issue":"21","key":"ref29","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1212\/WNL.0b013e3181c34b47","article-title":"Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease","volume":"73","author":"S Hoops","year":"2009","journal-title":"Neurology"},{"issue":"11","key":"ref30","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.parkreldis.2014.08.002","article-title":"Nadkarni N4, Tan LC. Montreal Cognitive Assessment for the screening and prediction of cognitive decline in early Parkinson&apos;s disease","volume":"20","author":"N Kandiah","year":"2014","journal-title":"Parkinsonism Relat Disord"},{"issue":"4","key":"ref31","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1212\/WNL.45.4.705","article-title":"Dementia in Parkinson\u2019s disease: a population-based study in ambulatory and institutionalized individuals","volume":"45","author":"F Tison","year":"1995","journal-title":"Neurology"},{"issue":"10","key":"ref32","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.parkreldis.2013.05.015","article-title":"Age at onset influences neurodegenerative processes underlying PD with levodopa-induced dyskinesias","volume":"19","author":"A Cerasa","year":"2013","journal-title":"Parkinsonism Relat Disord"},{"issue":"18","key":"ref33","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1212\/WNL.0b013e318253d54b","article-title":"Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study","volume":"78","author":"RN Alcalay","year":"2012","journal-title":"Neurology"},{"issue":"9","key":"ref34","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1212\/WNL.39.9.1187","article-title":"Effect of age at onset on progression and mortality in Parkinson&apos;s disease","volume":"39","author":"SG Diamond","year":"1989","journal-title":"Neurology"},{"issue":"1","key":"ref35","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.neurobiolaging.2014.07.043","article-title":"Correlation between decreased CSF \u03b1-synuclein and A\u03b21\u201342 in Parkinson disease","volume":"36","author":"C Buddhala","year":"2015","journal-title":"Neurobiol Aging"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.neulet.2012.11.004","article-title":"Total CSF alpha-synuclein is lower in de novo Parkinson patients than in healthy subjects","volume":"532","author":"B Mollenhauer","year":"2013","journal-title":"Neurosci Lett"},{"issue":"10","key":"ref37","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.biopsych.2008.02.016","article-title":"Cerebrospinal fluid biomarkers in Parkinson&apos;s disease with dementia and dementia with Lewy bodies","volume":"64","author":"L Parnetti","year":"2008","journal-title":"Biol Psychiatry"},{"issue":"3","key":"ref38","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.ncl.2009.04.004","article-title":"Etiology and pathogenesis of Parkinson disease","volume":"27","author":"AH Schapira","year":"2009","journal-title":"Neurol Clin"},{"issue":"9","key":"ref39","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s11064-006-9140-9","article-title":"Interaction between Abeta peptide and alpha synuclein: molecular mechanisms in overlapping pathology of Alzheimer\u2019s and Parkinson\u2019s in dementia with Lewy body disease","volume":"31","author":"PK Mandal","year":"2006","journal-title":"Neurochem Res"},{"issue":"21","key":"ref40","doi-asserted-by":"crossref","first-page":"7281","DOI":"10.1523\/JNEUROSCI.0490-10.2010","article-title":"Synergistic Interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline","volume":"30","author":"LK Clinton","year":"2010","journal-title":"J Neurosci"},{"issue":"5619","key":"ref41","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1126\/science.1082324","article-title":"Initiation and synergistic fibrillization of tau and alpha-synuclein","volume":"300","author":"BI Giasson","year":"2003","journal-title":"Science"},{"issue":"10","key":"ref42","doi-asserted-by":"crossref","first-page":"e26609","DOI":"10.1371\/journal.pone.0026609","article-title":"Tau enhances alpha-synuclein aggregation and toxicity in cellular models of synucleinopathy","volume":"6","author":"N Badiola","year":"2011","journal-title":"PLoS ONE"},{"issue":"2","key":"ref43","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1212\/01.wnl.0000327098.86861.d4","article-title":"A multidisciplinary study of patients with early-onset PD with and without parkin mutations","volume":"72","author":"E Lohmann","year":"2009","journal-title":"Neurology"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3389\/fneur.2013.00160","article-title":"Tangles, Toxicity, and Tau Secretion in AD\u2014New Approaches to a Vexing Problem","volume":"4","author":"KL Gendreau","year":"2013","journal-title":"Front Neurol"},{"issue":"Suppl 1","key":"ref45","first-page":"S67","article-title":"Molecular mechanisms of amyloid oligomers toxicity","volume":"33","author":"R Kayed","year":"2013","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"ref46","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/mds.26369","article-title":"Striatal and Cortical \u03b2-Amyloidopathy and Cognition in Parkinson&apos;s Disease","volume":"31","author":"N Shah","year":"2016","journal-title":"Mov Disord"},{"issue":"12","key":"ref47","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1212\/WNL.0b013e3181f39a78","article-title":"CSF amyloid \u03b2 1\u201342 predicts cognitive decline in Parkinson disease","volume":"75","author":"A Siderowf","year":"2010","journal-title":"Neurology"},{"issue":"20","key":"ref48","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1212\/WNL.0000000000000425","article-title":"CSF A\u03b242 predicts early-onset dementia in Parkinson disease","volume":"82","author":"G Alves","year":"2014","journal-title":"Neurology"},{"issue":"10","key":"ref49","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1212\/01.wnl.0000271375.37131.04","article-title":"Longitudinal changes of CSF biomarkers in memory clinic patients","volume":"69","author":"FH Bouwman","year":"2007","journal-title":"Neurology"},{"issue":"7","key":"ref50","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1007\/s00259-009-1063-7","article-title":"Association between FDG uptake, CSF biomarkers and cognitive performance in patients with probable Alzheimer&apos;s disease","volume":"36","author":"S Arlt","year":"2009","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"ref51","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s00702-007-0629-4","article-title":"Tauopathies and synucleinopathies: do cerebrospinal fluid beta-amyloid peptides reflect disease-specific pathogenesis?","volume":"114","author":"B Mollenhauer","year":"2007","journal-title":"J Neural Transm"},{"issue":"1\u20132","key":"ref52","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.brainresbull.2008.01.010","article-title":"CSF phosporylated TAU protein levels correlate with cerebral glucose metabolism assessed with PET in Alzheimer&apos;s disease","volume":"76","author":"R Ceravolo","year":"2008","journal-title":"Brain Res Bull"},{"issue":"8","key":"ref53","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.parkreldis.2012.04.028","article-title":"Grey matter volume correlates of cerebrospinal markers of Alzheimer-pathology in Parkinson&apos;s disease and related dementia","volume":"18","author":"Y Compta","year":"2012","journal-title":"Parkinsonism Relat Disord"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0164762","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T01:50:46Z","timestamp":1540259446000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0164762"}},"subtitle":[],"editor":[{"given":"Kewei","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2016,10,20]]},"references-count":53,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2016,10,20]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0164762","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,20]]}}}